Evidence map›Paper›PMID 42780687›Full record

ArticleEJHaem2026

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Durable Remission in Blast-Phase Chronic Myeloid Leukemia Presenting as Early T-Cell Precursor Acute Lymphoblastic Leukemia.

Takafumi Tsushima, Yukiko Konishi, Natsumi Yoda, Koichiro Wada, Kento Okamoto, Kosuke Matsuo, Shuntaro Isogai, Sonoko Shimoji, Yoshikazu Utsu, Shin-Ichi Masuda and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takafumi TsushimaDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Yukiko KonishiDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Natsumi YodaDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Koichiro WadaDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Kento OkamotoDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Kosuke MatsuoDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Shuntaro IsogaiDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Sonoko ShimojiDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Yoshikazu UtsuDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Shin-Ichi MasudaDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.
Nobuyuki AotsukaDepartment of Hematology and Oncology Japanese Red Cross Narita Hospital Narita Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The presentation of chronic myeloid leukemia (CML) in the blast phase as early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is very rare. As previously reported, in contrast to B-ALL, the prognosis is poor. Case Presentation: We encountered a patient with blast phase CML presenting as ETP-ALL. The patient responded to treatment with dasatinib and Hyper CVAD. However, the BCR::ABL1 transcript levels remained positive, and the patient demonstrated resistance to switching to ponatinib and other agents. Eventually, the patient underwent allogeneic hematopoietic stem cell transplantation (HSCT) and has maintained long-term molecular remission. Conclusion: HSCT following remission induction therapy, inclusive of TKIs, may enhance prognosis for patients with blast phase CML presenting as ETP-ALL. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.

Identifiers

PMID42780687
PMCPMC13598679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.